Peritoneum cancer

Summary

Peritoneum cancer (MONDO:0002087) is a cancer (an umbrella term covering 6 Mondo subtypes) with 1 cohort gene (1 CIViC-evidence somatic driver; 1 ClinVar predisposition record) and 349 clinical trials. Top therapeutic interventions include cisplatin, topotecan, and carboplatin.

At a glance

• Classification: Cancer
• Umbrella term: 6 Mondo subtypes
• Cohort genes: 1
• ClinVar variants: 1
• Clinical trials: 349

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	peritoneum cancer
Mondo ID	MONDO:0002087
DOID	DOID:1725
ICD-11	315445782
NCIT	C3538
SNOMED CT	363492001
UMLS	C0153467
MedGen	102270
Anatomy (UBERON)	UBERON:0002358
Is cancer (heuristic)	yes

Also known as: cancer of peritoneum · cancer of the peritoneum · malignant neoplasm of peritoneum · malignant peritoneal neoplasm · malignant peritoneum neoplasm · peritoneal cancer · peritoneal cavity cancer · peritoneum cancer

Data availability: 1 ClinVar variant.

Disease family

An umbrella term covering 6 Mondo subtypes.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › peritoneum cancer

Related subtypes (32): respiratory system cancer, immune system cancer, musculoskeletal system cancer, integumentary system cancer, cardiovascular cancer, reproductive system cancer, malignant giant cell tumor, digestive system cancer, lipomatous cancer, thoracic cancer, malignant glomus tumor, malignant mesenchymoma, carcinoma, sarcoma, blastoma, head and neck cancer, malignant mixed neoplasm, nervous system cancer, retroperitoneal cancer, malignant germ cell tumor, malignant mesothelioma, malignant urinary system neoplasm, childhood malignant neoplasm, anaplastic cancer, malignant spindle cell neoplasm, high grade malignant neoplasm, malignant endocrine neoplasm, malignant soft tissue neoplasm, secondary malignant neoplasm, refractory malignant neoplasm, malignant adenoma, cancer of unknown primary site

Subtypes (6): round ligament malignant neoplasm, peritoneal carcinoma, malignant peritoneal solitary fibrous tumor, malignant peritoneal mesothelioma, malignant peritoneal germ cell tumor, peritoneal carcinomatosis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

ClinVar germline variants

1 retrieved; paginated sample, class counts are floors:

1 pathogenic

ClinVar	Variant (HGVS)	Gene	Classification	Review
91612	NM_007294.4(BRCA1):c.3672del (p.Cys1225fs)	BRCA1	Pathogenic	reviewed by expert panel

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 9 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Somatic driver evidence (intOGen + CIViC, cohort fanout)

Gene	intOGen role	Cancer types	CIViC
BRCA1	LoF	BLCA,BRCA,MEL,OVT	CIViC #6

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
BRCA1	Orphanet:1331	Familial prostate cancer
BRCA1	Orphanet:1333	Familial pancreatic carcinoma
BRCA1	Orphanet:145	Hereditary breast and/or ovarian cancer syndrome
BRCA1	Orphanet:168829	Primary peritoneal carcinoma
BRCA1	Orphanet:227535	Hereditary breast cancer
BRCA1	Orphanet:667662	Breast implant-associated anaplastic large cell lymphoma
BRCA1	Orphanet:694963	Inflammatory breast cancer
BRCA1	Orphanet:70567	Cholangiocarcinoma
BRCA1	Orphanet:84	Fanconi anemia

Cohort genes → proteins

1 cohort genes, 1 distinct canonical proteins.

Evidence partition

Subset	Genes
multi_evidence	1

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
BRCA1	HGNC:1100	ENSG00000012048	P38398	Breast cancer type 1 susceptibility protein	clinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
BRCA1	Breast cancer type 1 susceptibility protein	E3 ubiquitin-protein ligase that specifically mediates the formation of ‘Lys-6’-linked polyubiquitin chains and plays a central role in DNA repair by facilitating cellular responses to DNA damage.

Protein-family classification

Druggable: 0 · Difficult: 1 · Unknown: 0 · Druggable fraction: 0.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Transcription factor	1	8.3×	0.121

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
BRCA1	Transcription factor	no	2.3.2.27	BRCT_dom, Znf_RING, BRCA1

Expression context

Cohort genes with no expression data: 0.

1 cohort gene are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	1
unknown	0

Top tissues across cohort

Tissue	Cohort genes
male germ line stem cell (sensu Vertebrata) in testis	1
primordial germ cell in gonad	1
ventricular zone	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
BRCA1	208	ubiquitous	marker	ventricular zone, male germ line stem cell (sensu Vertebrata) in testis, primordial germ cell in gonad

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
BRCA1	9,064

Structural data

PDB: 1 · AlphaFold-only: 0 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
BRCA1	P38398	33

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 59. Enrichment computed across 1 evidence-associated genes (1 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
Defective DNA double strand break response due to BRCA1 loss of function	1	5710.0×	0.005	BRCA1
Defective DNA double strand break response due to BARD1 loss of function	1	5710.0×	0.005	BRCA1
Regulation of MITF-M-dependent genes involved in DNA replication, damage repair and senescence	1	1631.4×	0.009	BRCA1
Defective homologous recombination repair (HRR) due to PALB2 loss of function	1	951.7×	0.009	BRCA1
Diseases of DNA Double-Strand Break Repair	1	815.7×	0.009	BRCA1
Defective homologous recombination repair (HRR) due to BRCA2 loss of function	1	815.7×	0.009	BRCA1
Resolution of D-Loop Structures	1	634.4×	0.009	BRCA1
Diseases of DNA repair	1	571.0×	0.009	BRCA1
DNA Double Strand Break Response	1	475.8×	0.009	BRCA1
Impaired BRCA2 binding to PALB2	1	456.8×	0.009	BRCA1
Defective homologous recombination repair (HRR) due to BRCA1 loss of function	1	423.0×	0.009	BRCA1
Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function	1	423.0×	0.009	BRCA1
Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function	1	423.0×	0.009	BRCA1
Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA)	1	393.8×	0.009	BRCA1
Homologous DNA Pairing and Strand Exchange	1	380.7×	0.009	BRCA1
Homology Directed Repair	1	308.6×	0.009	BRCA1
HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA)	1	308.6×	0.009	BRCA1
Impaired BRCA2 binding to RAD51	1	308.6×	0.009	BRCA1
Metalloprotease DUBs	1	300.5×	0.009	BRCA1
Resolution of D-loop Structures through Holliday Junction Intermediates	1	300.5×	0.009	BRCA1
HDR through Single Strand Annealing (SSA)	1	292.8×	0.009	BRCA1
Transcriptional Regulation by E2F6	1	292.8×	0.009	BRCA1
Meiosis	1	285.5×	0.009	BRCA1
Presynaptic phase of homologous DNA pairing and strand exchange	1	271.9×	0.009	BRCA1
DNA Double-Strand Break Repair	1	248.3×	0.010	BRCA1
Reproduction	1	190.3×	0.011	BRCA1
HDR through Homologous Recombination (HRR)	1	190.3×	0.011	BRCA1
TP53 Regulates Transcription of DNA Repair Genes	1	181.3×	0.011	BRCA1
MITF-M-dependent gene expression	1	181.3×	0.011	BRCA1
SUMO E3 ligases SUMOylate target proteins	1	178.4×	0.011	BRCA1

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
cellular response to indole-3-methanol	1	3370.4×	0.004	BRCA1
chordate embryonic development	1	2808.7×	0.004	BRCA1
negative regulation of centriole replication	1	2407.4×	0.004	BRCA1
DNA strand resection involved in replication fork processing	1	2106.5×	0.004	BRCA1
DNA damage tolerance	1	1685.2×	0.004	BRCA1
homologous recombination	1	1404.3×	0.004	BRCA1
negative regulation of intracellular estrogen receptor signaling pathway	1	1123.5×	0.004	BRCA1
regulation of DNA damage checkpoint	1	1123.5×	0.004	BRCA1
negative regulation of gene expression via chromosomal CpG island methylation	1	1053.2×	0.004	BRCA1
protein K6-linked ubiquitination	1	991.3×	0.004	BRCA1
random inactivation of X chromosome	1	936.2×	0.004	BRCA1
negative regulation of reactive oxygen species metabolic process	1	936.2×	0.004	BRCA1
negative regulation of fatty acid biosynthetic process	1	887.0×	0.004	BRCA1
mitotic G2/M transition checkpoint	1	802.5×	0.004	BRCA1
negative regulation of extrinsic apoptotic signaling pathway via death domain receptors	1	581.1×	0.005	BRCA1
positive regulation of vascular endothelial growth factor production	1	495.6×	0.005	BRCA1
mitotic G2 DNA damage checkpoint signaling	1	443.5×	0.005	BRCA1
response to ionizing radiation	1	411.0×	0.005	BRCA1
cellular response to ionizing radiation	1	411.0×	0.005	BRCA1
positive regulation of DNA repair	1	358.6×	0.006	BRCA1
fatty acid biosynthetic process	1	351.1×	0.006	BRCA1
centrosome cycle	1	337.0×	0.006	BRCA1
intrinsic apoptotic signaling pathway in response to DNA damage	1	324.1×	0.006	BRCA1
negative regulation of cell cycle	1	290.6×	0.006	BRCA1
regulation of DNA repair	1	276.3×	0.006	BRCA1
protein autoubiquitination	1	234.1×	0.007	BRCA1
double-strand break repair	1	203.0×	0.008	BRCA1
chromosome segregation	1	173.7×	0.009	BRCA1
cellular response to tumor necrosis factor	1	163.6×	0.009	BRCA1
double-strand break repair via homologous recombination	1	156.0×	0.009	BRCA1

Therapeutics

Drug target analysis

Approved (phase 4): 1 · Phase ≥3: 1 · Phased (≥1): 1 · Undrugged: 0

Druggability breadth: 1 of 1 evidence-associated genes (100%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

Symbol	Example approved molecule
BRCA1	RIBOFLAVIN

Top cohort targets by molecule count

Symbol	Molecules	Max phase
BRCA1	12	4

Drugs targeting cohort genes (top 30)

Molecule	Max phase	Targets in cohort
RIBOFLAVIN	4	BRCA1
DAUNORUBICIN HYDROCHLORIDE	4	BRCA1
TOPOTECAN HYDROCHLORIDE	4	BRCA1
DAUNORUBICIN	4	BRCA1
DOXORUBICIN HYDROCHLORIDE	4	BRCA1
MESALAMINE	4	BRCA1
DIPYRIDAMOLE	4	BRCA1
CURCUMIN	3	BRCA1
SURAMIN	3	BRCA1
SURAMIN HEXASODIUM	3	BRCA1
SODIUM TANSHINONE IIA SULFONATE	2	BRCA1
HOMIDIUM BROMIDE	2	BRCA1

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 1.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
BRCA1	13	Binding:9, Functional:4

Cohort enzymes (BRENDA EC)

Symbol	EC numbers	Names
BRCA1	2.3.2.27	RING-type E3 ubiquitin transferase

Pharmacogenomics

Cohort genes with a PharmGKB record: 1; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Drug repurposing candidates

12 approved/phased drugs hit cohort targets but don’t yet appear in disease-level clinical trials. Target-inhibition rationale is strongest for cancer driver genes; a bioactivity hit is a screening signal, not a treatment claim.

Compound	Max phase	Cohort target (bioactivity)
RIBOFLAVIN	4	BRCA1
DAUNORUBICIN HYDROCHLORIDE	4	BRCA1
TOPOTECAN HYDROCHLORIDE	4	BRCA1
DAUNORUBICIN	4	BRCA1
DOXORUBICIN HYDROCHLORIDE	4	BRCA1
MESALAMINE	4	BRCA1
DIPYRIDAMOLE	4	BRCA1
CURCUMIN	3	BRCA1
SURAMIN	3	BRCA1
SURAMIN HEXASODIUM	3	BRCA1
SODIUM TANSHINONE IIA SULFONATE	2	BRCA1
HOMIDIUM BROMIDE	2	BRCA1

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	1	BRCA1
B	Phased (≥1) drug, not yet approved	0
C	Druggable family + PDB, no drug	0
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	0

Undrugged target profiles

0 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Clinical trials & evidence

Clinical trials

Clinical trials: 349.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	152
PHASE1	77
Not specified	56
PHASE3	34
PHASE1/PHASE2	22
PHASE2/PHASE3	4
EARLY_PHASE1	4

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02758951	PHASE2/PHASE3	ACTIVE_NOT_RECRUITING	Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases
NCT04498117	PHASE3	ACTIVE_NOT_RECRUITING	Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery
NCT05009082	PHASE3	RECRUITING	Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer
NCT05445778	PHASE3	ACTIVE_NOT_RECRUITING	Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
NCT00002717	PHASE3	COMPLETED	Paclitaxel and Cisplatin in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer
NCT00002894	PHASE3	COMPLETED	Platinum-based Chemotherapy With or Without Paclitaxel in Treating Patients With Relapsed Ovarian Cancer
NCT00002895	PHASE3	COMPLETED	Early Chemotherapy Based on CA 125 Level Alone Compared With Delayed Chemotherapy in Treating Patients With Recurrent Ovarian Epithelial , Fallopian Tube, or Primary Peritoneal Cancer
NCT00003120	PHASE3	COMPLETED	S9701 Paclitaxel in Treating Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission
NCT00003322	PHASE3	COMPLETED	Combination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian Cancer
NCT00003636	PHASE3	COMPLETED	Chemotherapy Plus Surgery in Treating Patients With Stage III or Stage IV Ovarian, Peritoneal, or Fallopian Tube Cancer
NCT00003880	PHASE2/PHASE3	TERMINATED	Paclitaxel Plus Carboplatin With or Without SCH-58500 in Treating Patients With Newly Diagnosed Stage III Ovarian or Stage III Primary Peritoneal Cancer
NCT00003998	PHASE3	COMPLETED	Carboplatin Plus Paclitaxel or Docetaxel in Treating Patients With Ovarian Epithelial Cancer
NCT00004115	PHASE3	UNKNOWN	Monoclonal Antibody Therapy in Treating Patients With Ovarian Cancer or Primary Peritoneal Cancer in Remission Following Surgery and Chemotherapy
NCT00004934	PHASE3	COMPLETED	Paclitaxel and Carboplatin With or Without Epirubicin in Treating Patients With Stage IIB, Stage III, or Stage IV Invasive Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer
NCT00028743	PHASE3	COMPLETED	Combination Chemotherapy Regimens in Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
NCT00041080	PHASE3	COMPLETED	Tamoxifen Compared With Thalidomide in Treating Women With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
NCT00043082	PHASE3	COMPLETED	S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer
NCT00045461	PHASE2/PHASE3	UNKNOWN	Combination Chemotherapy With or Without Whole-Body Hyperthermia in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer
NCT00075712	PHASE2/PHASE3	COMPLETED	Timing of Surgery and Chemotherapy in Treating Patients With Newly Diagnosed Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
NCT00098878	PHASE3	COMPLETED	Carboplatin in Treating Patients With Stage IC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT00245050	PHASE3	COMPLETED	Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer
NCT00263822	PHASE3	COMPLETED	Erlotinib or Observation in Treating Patients Who Have Undergone First-Line Chemotherapy for Ovarian Cancer, Peritoneal Cancer, or Fallopian Tube Cancer
NCT00483782	PHASE3	COMPLETED	Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer
NCT00693342	PHASE3	WITHDRAWN	Vaccine Therapy and OPT-821 or OPT-821 Alone in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer in Complete Remission
NCT00769405	PHASE3	COMPLETED	Systemic Chemotherapy With or Without Intraperitoneal Chemohyperthermia in Treating Patients Undergoing Surgery for Peritoneal Carcinomatosis From Colorectal Cancer
NCT00850772	PHASE3	COMPLETED	Early Post-Operative Enteral Feeding in Patients With Advanced Epithelial Ovarian Cancer
NCT01493505	PHASE3	TERMINATED	TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer
NCT01704651	PHASE3	COMPLETED	Accelerating Gastrointestinal Recovery
NCT01968213	PHASE3	COMPLETED	Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3)
NCT02158988	PHASE3	COMPLETED	Cytoreductive Surgery (CRS) With/Without HIPEC in Gastric Cancer With Peritoneal Carcinomatosis
NCT02728622	PHASE3	COMPLETED	Chemotherapy vs Hormonal Treatment in Platinum-resistant Ovarian Cancer Resistant or Refractory to Platinum and Taxane
NCT02855944	PHASE3	COMPLETED	ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients
NCT03359811	PHASE3	COMPLETED	Four Quadrants Transverse Abdominus Plane (4Q-TAP) Block With Plain and Liposomal Bupivacaine vs. Thoracic Epidermal Analgesia (TEA) in Patients Undergoing Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy (CRS-HIPEC) on an Enhanced Recovery Pathway
NCT03693248	PHASE3	UNKNOWN	Reduction Of Cycles of neOadjuvant Chemotherapy for Advanced Epithelial Ovarian, Fallopian and Primary Peritoneal Cancer
NCT04209855	PHASE3	COMPLETED	A Study of Mirvetuximab Soravtansine vs. Investigator’s Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression
NCT04296890	PHASE3	COMPLETED	A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
NCT04676334	PHASE3	COMPLETED	CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib
NCT05622890	PHASE3	UNKNOWN	A Single-arm Clinical Trial of IMGN853 in Chinese Adult Patients With Platinum-resistant, Epithelial Ovarian Cancer
NCT02873962	PHASE2	ACTIVE_NOT_RECRUITING	A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib
NCT03280511	PHASE2	RECRUITING	Adjuvant Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) in Resected High Risk Colon Cancer Patients

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CISPLATIN	4	21
TOPOTECAN	4	12
CARBOPLATIN	4	8
PACLITAXEL	4	8
RUCAPARIB	4	6
MIRVETUXIMAB SORAVTANSINE	4	5
TAMOXIFEN	4	5
ERLOTINIB HYDROCHLORIDE	4	4
DOCETAXEL ANHYDROUS	4	3
PYRIDOXINE	4	3
AMIFOSTINE	4	2
DOXORUBICIN	4	2
NIRAPARIB	4	2
ALVIMOPAN	4	1
BUPIVACAINE	4	1
EPIRUBICIN HYDROCHLORIDE	4	1
ETOPOSIDE PHOSPHATE	4	1
FLOXURIDINE	4	1
GANCICLOVIR	4	1
IFOSFAMIDE	4	1
LEUCOVORIN	4	1
OCTREOTIDE ACETATE	4	1
OXALIPLATIN	4	1
THALIDOMIDE	4	1
THIOTEPA	4	1
OREGOVOMAB	3	4
EXATECAN	3	2
ARZOXIFENE HYDROCHLORIDE	2	1
LY-295501	2	1
CHEMBL48	0	8